地尔硫卓与贝前列素对健康青年男性高原暴露后运动耐力的影响  

Impact of diltiazem/beprost on exercise endurance in healthy young males after high altitude exposure

作　　者：李相俊 王秀亮 刘方洲 周亮 张伦伟 李军 马峰琴 卜学惠 常妮 LI Xiangjun;WANG Xiuliang;LIU Fangzhou;ZHOU Liang;ZHANG Lunwei;LI Jun;MA Fengqin;BU Xuehui;CHANG Ni(Department of Cardiovascular and Respiratory Diseases,No.952 Hospital of Chinese PLA Army,Golmud,Qinghai Province,816099,China)

机构地区：[1]陆军第952医院心血管呼吸内科,青海格尔木816099

出　　处：《陆军军医大学学报》2023年第6期480-485,共6页Journal of Army Medical University

基　　金：全军医学科技青年培育项目(15QNP095)。

摘　　要：目的探讨单用或联合使用地尔硫卓、贝前列素对提高健康青年男性高原暴露后运动耐力的有效性及安全性。方法从2017年7月至2020年8月共纳入200例世居平原非藏族健康青年男性作为研究对象,从平原进驻高原(海拔2815 m)后随机分为4组,A组:口服地尔硫卓缓释胶囊安慰剂90 mg,1次/d;贝前列素安慰剂40μg,3次/d。B组:口服地尔硫卓缓释胶囊安慰剂90 mg,1次/d;贝前列素40μg,3次/d。C组:口服地尔硫卓缓释胶囊90 mg,1次/d;贝前列素安慰剂40μg,3次/d。D组:口服地尔硫卓缓释胶囊90 mg,1次/d;贝前列素40μg,3次/d。连续干预5 d后,对比干预前后6分钟步行距离(6 minute walk distance,6MWD)及脉搏血氧饱和度(pulse oxygen saturation,SpO_(2))、血压(blood pressure,BP)、肺动脉收缩压(pulmonary artery systolic pressure,PASP)与不良反应等指标。结果13例失访,最终187例纳入数据统计。干预后B、C、D组6MWD均显著提高(t=-9.048、-9.555、-12.903,95%CI:-45.582~-28.984、-46.391~-30.262、-63.205~-46.128,P<0.05);B、C、D组PASP均显著降低(t=10.219、9.380、11.069,95%CI:2.304~3.435、2.277~3.519、2.636~3.809,P<0.05);C、D组SpO_(2)显著升高(t=-4.071、-4.655,95%CI:-1.311~-0.444、-2.569~-1.031,P<0.05)。干预后各组间比较,B、C、D组6MWD均较A组显著提高(F=7.246,P<0.05);PASP均较A组显著降低(F=10.421,P<0.05);D组SpO_(2)较A、B、C组显著升高(F=6.896,P<0.05)。BP、不良反应均无显著性差异。结论单用或联合使用地尔硫卓、贝前列素均能提升健康青年男性高原暴露后运动耐力,安全性较好。ObjectiveTo investigate the efficacy and safety of single or combined use of diltiazem and beprost on exercise endurance improvement after high altitude exposure in healthy young males.MethodsA total of 200 non-Tibet health young men who have inhabited in plain areas for generations and were transferred from plain to plateau(2815 m)from July 2017 to August 2020 were recruited in the study.The participants were randomly assigned in group A(90 mg diltiazem sustained-release capsule placebo once a day and 40μg beraprost placebo 3 times a day),B(90 mg diltiazem sustained-release capsule placebo once a day and 40μg beraprost 3 times a day).C(90 mg diltiazem sustained-release capsules once a day and 40μg beraprost placebo 3 times a day)and D(90 mg diltiazem sustained-release capsules once a day and 40μg beraprost 3 times a day).After 5 days’continuous administration of drug and placebo,results of 6-minute walk distance(6MWD)test,pulse oxygen saturation(SpO_(2)),blood pressure(BP)and pulmonary artery systolic pressure(PASP),and incidence of adverse reactions before and after intervention were collected and compared among the groups.ResultsThere were 13 cases lost during follow-up,and finally 187 participants were included.After intervention,the results of 6MWD test were obviously improved(t=-9.048,-9.555,-12.903,95%CI:-45.582~-28.984,-46.391~-30.262,-63.205~-46.128,P<0.05),PASP values(t=10.219,9.380,11.069,95%CI:2.304~3.435,2.277~3.519,2.636~3.809,P<0.05)were significantly decreased in group B,group C and group D,and the SpO_(2) values(t=-4.071,-4.655,95%CI:-1.311~-0.444,-2.569~-1.031,P<0.05)were greatly increased in groups C and D.In addition,the participants from the groups B,C and D obtained significantly prolonged 6MWD results(F=7.246,P<0.05)and lower PASP value(F=10.421,P<0.05)after the treatment when compared with those of group A.Moreover,SpO_(2) in group D was significantly higher than that in groups A,B and C(F=6.896,P<0.05).There were no significant difference in BP value and incidence of adverse reactio

关 键 词：地尔硫卓 贝前列素 运动耐力 影响 高原 

分 类 号：R339.4[医药卫生—人体生理学] R339.54[医药卫生—基础医学] R969.4